{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-22-008523","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.093899+00:00","generated_at":"2026-06-21T21:57:59.613670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VolitionRx reports Q3 2022 results; cash $16.4M, monthly burn ~$2.3M; new global vet supply deal","bullets":["Cash at Sep 30: $16.4M; net cash used in operations ~$2.3M/month.","Raised ~$6.4M net from public offering; secured $1.5M non-dilutive from Namur Invest.","Post-quarter: signed global supply agreement for Nu.Q Vet Cancer Test with a pet healthcare market leader; launched via Heska in U.S. and soon Europe.","Appointed DXOCRO for U.S. clinical validation studies of Nu.Q NETs and Cancer tests; pre-submission to FDA anticipated in 2023.","Started lung cancer biomarker study with Hospices Civils de Lyon (ILYAD) to develop national screening program."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-22-008523","json":"https://secwatch.observer/filing/0001477932-22-008523.json","markdown":"https://secwatch.observer/filing/0001477932-22-008523.md","text":"https://secwatch.observer/filing/0001477932-22-008523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793222008523/0001477932-22-008523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793222008523/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:57:59.613670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0da240b9d6b26681168547e2e5215e6dd2580581","claim":"VOLITIONRX LTD reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793222008523/0001477932-22-008523-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}